Atxn2 (human) recombinant (partial protein gst tag) 25 µg
Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
Points clés
Used for AP, Array, ELISA, WB-Re
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. Defects in this gene are the cause of spinocerebellar ataxia type 2 (SCA2). SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is caused by expansion of a CAG repeat in the coding region of this gene. Longer expansions result in earlier onset of the disease. Alternatively spliced transcript variants encoding different isoforms have been identified but their full length sequence has not been determined. [provided by RefSeq]
Garantie
Garantie 0 Mois
Description
Used for AP, Array, ELISA, WB-Re
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. Defects in this gene are the cause of spinocerebellar ataxia type 2 (SCA2). SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is caused by expansion of a CAG repeat in the coding region of this gene. Longer expansions result in earlier onset of the disease. Alternatively spliced transcript variants encoding different isoforms have been identified but their full length sequence has not been determined. [provided by RefSeq]
Caractéristiques
- Certification
- RUO
- Type d'antibiotique
- non
- Type d'enzyme
- non
- Domaine de recherche
- protéomique
- Type de protéine
- oui
- Marque
- ABNOVA
- Fournisseur
- FISHER SCIENTIFIC S.A.S.
- Référence distributeur
- 16154935
- Dispositif stérile
- non
- Marquage CE DIV
- non
- Code à barre
- non
- Type d'acide nucléique extrait
- non
- Origine humaine
- non
- Sans composant animal
- non
- Vendu par
- 25 ug
- Délai de péremption à la date de livraison
- 12 mois
- Température de conservation (°C)
- -80 °C
- Température de transport
- carboglace
- Soumis à carboglace
- oui
- Classification REACH
- non
- Code douanier
- 38229000
- Nomenclature Nacres
- NA.55
- Nomenclature IFPEN
- NA.55
- Nomenclature IRSN
- 273
- Nomenclature INSERM
- NA.NA55
- Nomenclature CHU
- 18.551
- Nomenclature DGOS
- LD10AOOO
- Nomenclature CEA
- SGP01
- Nomenclature CNRS
- NA55
- Reprise en cas d’erreur client
- non
- Type de produit
- protéine
- Libellé produit fabricant
- 25ug atxn2 (human) recombinant protein (q01)
- Type d’application
- ELISA, western blot
- Lieu de stockage
- France
- Autres caractéristiques
- Abnova Human ATXN2 Partial ORF (NP_002964, 1214 a.a. - 1313 a.a.) Recombinant Protein with GST-tag at N-terminal, Quantity: 25 ug, Format: Liquid, Formulation: 50mM Tris-HCI, 10mM reduced Glutathione, pH-8.0 in the elution buffer., Host Species: Whea
- Lieu de fabrication
- Taïwan
- Matière dangereuse
- non
- Type d'échantillon
- protéine
- Quantité
- N/A
- Référence fabricant
- H00006311-Q01

